A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis

NCT03445013 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: SB414 6%
DRUG: Vehicle

Sponsor

Novan, Inc.

Collaborators

[object Object]